Literature DB >> 21948570

A new risk factor for the development of non-alcoholic fatty liver disease: HLA complex genes.

Mehmet Celıkbılek1, Haldun Selçuk, Uğur Yilmaz.   

Abstract

BACKGROUND/AIMS: Several studies have emphasized the role of genetic factors in susceptibility to non-alcoholic fatty liver disease. The aim of this study was to examine the possible influence of human leukocyte antigen in the development of non-alcoholic fatty liver disease.
METHODS: Between January 2000 and January 2008, data of 655 donor candidates were examined from routinely performed abdominal ultrasonography and for aspartate aminotransferase, alanine aminotransferase, hepatitis B virus, hepatitis C virus, cytomegalovirus, human immunodeficiency virus, hepatic functions, and human leukocyte antigen class I and II antigens; data of 116 healthy candidates were also included in this study. To reduce the influence of possible confounding factors, we excluded diseases known to be associated with non-alcoholic fatty liver disease like obesity, diabetes mellitus, coronary artery disease, hyperlipidemia, and metabolic syndrome. Non-alcoholic fatty liver disease was diagnosed in 66 individuals (33 male, median age: 53.8 [range, 32-77 years]) by means of ultrasonography data, and 50 individuals, whose ultrasonography data did not show hepatosteatosis, comprised the control group (20 male, median age: 44.6 [range, 26-71 years]).
RESULTS: Human leukocyte antigen-B65 (28.8% vs 0%, p<0.001) and DQ5 (40.7% vs 16.1%, p<0.05) were found to be expressed significantly more in non-alcoholic fatty liver disease compared with controls. Serum alanine aminotransferase (27.1 IU/L vs 20 IU/L, p<0.05) was significantly higher in the study group.
CONCLUSIONS: Our preliminary study suggests that human leukocyte antigen plays a role in the pathogenesis of non-alcoholic fatty liver disease; however, more studies are needed to clarify these data.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21948570     DOI: 10.4318/tjg.2011.0237

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  6 in total

1.  Host factors and typhoid fever-associated intestinal perforation in children in Nigeria.

Authors:  Subhash C Arya; Nirmala Agarwal
Journal:  Pediatr Surg Int       Date:  2012-05-31       Impact factor: 1.827

2.  HLA DQB1 alleles are related with nonalcoholic fatty liver disease.

Authors:  Levent Doganay; Seyma Katrinli; Yasar Colak; Ebubekir Senates; Ebru Zemheri; Oguzhan Ozturk; Feruze Yilmaz Enc; Ilyas Tuncer; Gizem Dinler Doganay
Journal:  Mol Biol Rep       Date:  2014-08-26       Impact factor: 2.316

3.  Genetic Factors Involved in the Development and Progression of Nonalcoholic Fatty Liver Disease.

Authors:  A M Amzolini; M Fortofoiu; S E Tudorica-Micu; M C Fortofoiu; D Neagoe; M Popescu; F Burada; C C Vere; T Ciurea
Journal:  Curr Health Sci J       Date:  2015-12-22

4.  Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease.

Authors:  Azza Karrar; Siddharth Hariharan; Yousef Fazel; Ali Moosvi; Mohamad Houry; Zahra Younoszai; Thomas Jeffers; Li Zheng; Otgonsuren Munkhzul; Sharon Hunt; Fanny Monge; Zachary Goodman; Zobair M Younossi
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

5.  Major Histocompatibility Complex Class I-Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver Disease.

Authors:  Azza Karrar; Bijal Rajput; Siddharth Hariharan; Dinan Abdelatif; Mohamad Houry; Ali Moosvi; Irfan Ali; Daisong Tan; Sohailla Noor; Donna Esmaeili; Sean Felix; Lakshmi Alaparthi; Munkhzul Otgonsuren; Brian Lam; Zachary D Goodman; Zobair M Younossi
Journal:  Hepatol Commun       Date:  2020-09-30

6.  Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice.

Authors:  Gilles Willemin; Catherine Roger; Armelle Bauduret; Kaori Minehira
Journal:  Int J Endocrinol       Date:  2013-04-24       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.